CIK 0000876343
- Non-accelerated filer
- Smaller reporting company
Lineage Cell Therapeutics, Inc.
Sign in to watch- Ticker
- LCTX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 943127919
- Phone
- +1 510-521-3390
- Business address
- 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008
- Former names
- BIOTIME INC
- 4 Open-market buy Director bought 1,000,000 shares at $2.50 ($2,500,000)
- 4 Open-market sale Chief Commercial Officer sold 30,000 shares at an average $3.07 ($91,980)
- 4 Open-market buy Director bought 300,000 shares at $2.45 ($735,000)
- 4 Open-market sale Director sold 300,000 shares at $2.45 ($735,000)
- 4 Open-market buy Director bought 300,000 shares at $2.44 ($730,500)
- 4 Open-market sale Director sold 300,000 shares at $2.44 ($730,500)
- 4 Open-market buy Director bought 2,000,000 shares at $2.52 ($5,040,000)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 500,000 shares at $3.74 ($1,870,000)
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 4 Exercise or conversion Sr. VP, COO, and CFO acquired 25,000 shares (option exercise)
- 4 Open-market buy Director bought 300,042 shares at an average $3.51 ($1,052,148)
- 4 Open-market sale Chief Commercial Officer sold 13,860 shares at an average $3.76 ($52,058)
Page 16 of 37 · 722 filings